Ameriprise
SOPH icon

Ameriprise’s SOPHiA GENETICS SOPH Stock Holding History

Ameriprise’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8M Buy
+2,216,752
New +$11.2M ﹤0.01% 1871

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $5.12B AUM 19.08% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
AWA
Alta Wealth Advisors Woburn, Massachusetts $369M AUM 45.79% 1-Year Est. Return

Ameriprise's SOPH Position: Q2 2026 in Review

Ameriprise opened a new position in SOPHiA GENETICS (SOPH) in Q2 2026: 2,216,752 shares worth $12.8M. The stake represents ﹤0.01% of the portfolio and ranks #1871 among its holdings.

68 funds tracked by Wall St. Rank hold SOPH as of Q2 2026.

  • Ameriprise held 2,216,752 shares of SOPHiA GENETICS worth $12.8M as of Q2 2026.
  • SOPHiA GENETICS was a new Ameriprise position in Q2 2026.
  • SOPHiA GENETICS made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1871 holding.
  • 68 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.